We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

4 hedge funds and large institutions have $840K invested in Decoy Therapeutics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

20% less funds holding

Funds holding: 5 → 4 (-1)

40% less capital invested

Capital invested by funds: $1.39M → $840K (-$554K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$160K

Top Sellers

Rank Fund Capital Flow
1
FAIM
Financial Advocates Investment Management
Washington
-$160K
2
TSS
Two Sigma Securities
New York
-$119K
3
Bank of America
Bank of America
North Carolina
-$10K

DCOY Hedge Fund Activity: Q4 2019 in Review

4 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q4 2019, worth a combined $840K — down 40% from $1.39M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of DCOY and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $160K. The largest seller was Financial Advocates Investment Management, exiting entirely with an estimated $160K sold.

  • 4 institutional investors held Decoy Therapeutics (DCOY) as of Q4 2019, down from 5 in Q3 2019.
  • Funds reported $840K of Decoy Therapeutics stock for Q4 2019, down 40% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q4 2019 and 2 closed out, a net change of -1 holder.
  • The largest Decoy Therapeutics buyer in Q4 2019 was Geode Capital Management, an estimated $160K added.
  • The largest Decoy Therapeutics seller in Q4 2019 was Financial Advocates Investment Management, an estimated $160K sold.

Based on aggregated 13F filings for Q4 2019.